Novavax, Inc. (NASDAQ:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Jeffrey Stoddard, M.D., to the position of Vice President, Medical Affairs. Dr. Stoddard’s efforts will be focused on external engagement with thought leaders, vaccine experts, policymakers and key stakeholders. He will also be responsible for evidence generation related to health economics and outcomes research.

Dr. Stoddard joins Novavax with more than 15 years of vaccine research and development experience and leadership roles. He was instrumental in the commercial launch of multiple vaccines and biologics including Synagis®, FluMist®, pandemic flu vaccines, Menveo® and Bexsero®. He was most recently Vice President, Medical Affairs & Medical Professional Services, at Alkermes plc, where he led medical affairs, and health economics and outcomes research. Prior to Alkermes, Dr. Stoddard held positions of increasing responsibility at Novartis Vaccines, Covance and MedImmune. Dr. Stoddard earned his medical degree from the University of Wisconsin Medical School, a Bachelor of Science degree from the University of Wisconsin-Madison, and completed a residency at Johns Hopkins Hospital and a postdoctoral fellowship in the Pew Health Policy program at the University of California, San Francisco.

“Dr. Stoddard is a foundational building block of the Novavax commercial team,” said John Trizzino, Senior Vice President, Commercial Operations. “His medical and healthcare policy experience will be critical as we develop our disease state awareness and vaccine policy strategy and we look forward to his leadership in educating healthcare providers in anticipation of the commercial launch of our respiratory syncytial virus F-protein nanoparticle vaccine candidate.” (Original Source)

Shares of Novavax closed yesterday at $6.92, down $0.62 or -8.22%. NVAX has a 1-year high of $15.01 and a 1-year low of $5.82. The stock’s 50-day moving average is $8.11 and its 200-day moving average is $9.47.

On the ratings front, Piper Jaffray analyst Edward Tenthoff reiterated a Buy rating on NVAX, with a price target of $15, in a report issued on December 15. The current price target implies an upside of 116.8% from current levels. According to, Tenthoff has a total average return of 4.6%, a 37.9% success rate, and is ranked #764 out of 3630 analysts.

Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.